Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised 13C-MRI and mass spectrometry imaging. | Synapse
March 3, 2026Open Access
Probing intratumoral metabolic compartmentalisation in a patient with fumarate hydratase-deficient renal cancer using clinical hyperpolarised 13C-MRI and mass spectrometry imaging.
Key Points
Metabolic compartmentalisation appears to differentiate tumor characteristics in renal cancer patients, leading to tailored treatment strategies.
13C-MRI revealed distinct metabolic profiles associated with fumarate hydratase deficiency in renal tumors, indicating potential biomarkers.
Mass spectrometry imaging provided detailed metabolic mapping of tumors, enhancing our understanding of intratumoral heterogeneity.
These findings highlight the importance of advanced imaging techniques in improving diagnostics for renal cancer patients.